Santaris Nabs Isis, Amgen Vets
Luke Timmerman10/28/09
Santaris Pharma, the Danish company that has pushed the first microRNA therapy into clinical trials, has recruited a pair of big name executives from Isis Pharmaceuticals and Amgen Ventures to help lead its new U.S. subsidiary in San Diego. Mark Wedel, the former chief medical officer at Carlsbad, CA-based Isis, will fill that same position at Santaris, while Stuart Mackey, the former managing director of Amgen Ventures, has joined Santaris as chief business officer. The two executives are part of Santaris’ U.S. growth strategy, which I described in a feature story last month.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
